Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation sequencing (NGS) for precise patient stratification and treatment selection in metastatic prostate cancer (mPC).
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.
